Jpmorgan Chase & CO Vincerx Pharma, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Vincerx Pharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 58 shares of VINC stock, worth $17. This represents 0.0% of its overall portfolio holdings.
Number of Shares
58Holding current value
$17% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding VINC
# of Institutions
28Shares Held
11MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY2.7MShares$838,2400.03% of portfolio
-
Prosight Management, LP Dallas, TX2.21MShares$684,0160.43% of portfolio
-
Sage Rhino Capital LLC1.7MShares$528,0580.28% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD892KShares$276,4320.02% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct674KShares$208,9990.0% of portfolio
About Vincerx Pharma, Inc.
- Ticker VINC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,189,800
- Market Cap $6.57M
- Description
- Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...